Loading...
SBS logo

Stratec SEXTRA:SBS Stock Report

Market Cap €272.9m
Share Price
€22.45
n/a
1Y-24.5%
7D1.4%
Portfolio Value
​
View

Stratec SE

XTRA:SBS Stock Report

Market Cap: €272.9m

Stratec (SBS) Stock Overview

Provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. More details

SBS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance4/6
Financial Health4/6
Dividends2/6

Rewards

Trading at 60.9% below our estimate of its fair value

Earnings are forecast to grow 21.6% per year

Earnings grew by 21.8% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Debt is not well covered by operating cash flow

Dividend of 2.67% is not well covered by free cash flows


SBS Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

SBS logo
Stratec

Aging Populations And Automation Will Spur Diagnostic Demand

Key Takeaways Structural upswing in system demand, operating leverage from automation, and a shift to higher-value products signal underestimated earnings and margin upside. Long-term OEM partnerships and rising emerging market investments position Stratec for sustained top-line growth and enhanced global market share.
View narrative
€51
FV
56.0% undervalued intrinsic discount
7.49%
Revenue growth p.a.
6
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SBS logo
Stratec

Weak Product Launches Will Drag Performance Despite Emerging Opportunity

Key Takeaways Slow adoption of new products and cautious customer spending are hampering recurring revenue growth and dampening near-term earnings visibility. Competitive pricing pressures, operational inefficiencies, and moderate demand could compress margins and delay targeted improvements in cash flow and profitability.
View narrative
€27
FV
16.9% undervalued intrinsic discount
4.12%
Revenue growth p.a.
8
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SBS logo
Stratec

SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures

Key Takeaways Increased demand for automated diagnostic solutions and consumables positions the company for recurring revenue growth and stronger margins amid healthcare digitalization. Investments in proprietary technologies, regulatory compliance, and operational efficiency are expected to drive long-term growth, margin improvement, and stable earnings.
View narrative
€32.42
FV
30.8% undervalued intrinsic discount
5.55%
Revenue growth p.a.
58
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
View Stock Community

Stratec SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for Stratec
Historical stock prices
Current Share Price€22.45
52 Week High€37.40
52 Week Low€19.58
Beta0.72
1 Month Change-3.85%
3 Month Change-28.39%
1 Year Change-24.54%
3 Year Change-72.11%
5 Year Change-81.90%
Change since IPO331.48%

Recent News & Updates

Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt

Nov 29
Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt

Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 11
Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt

Nov 29
Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt

Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 11
Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Investors Give Stratec SE (ETR:SBS) Shares A 35% Hiding

Nov 07
Investors Give Stratec SE (ETR:SBS) Shares A 35% Hiding

Getting In Cheap On Stratec SE (ETR:SBS) Might Be Difficult

Sep 23
Getting In Cheap On Stratec SE (ETR:SBS) Might Be Difficult

An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 34% Undervalued

Jun 17
An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 34% Undervalued

Why We're Not Concerned About Stratec SE's (ETR:SBS) Share Price

Apr 25
Why We're Not Concerned About Stratec SE's (ETR:SBS) Share Price
User avatar

Efficiency Measures And Acquisitions Like Natech Will Boost Future Market Presence

Efficiency measures and cost discipline initiatives could enhance net margins as market conditions stabilize.

An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 42% Undervalued

Jan 18
An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 42% Undervalued

With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For

Nov 09
With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For

Returns At Stratec (ETR:SBS) Appear To Be Weighed Down

Oct 26
Returns At Stratec (ETR:SBS) Appear To Be Weighed Down

Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year

May 11
Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year

Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55

Apr 11
Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55

Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next

Apr 01
Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next

Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55

Mar 28
Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55

Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?

Dec 21
Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?

Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement

Nov 03
Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement

We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt

Oct 19
We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt

Return Trends At Stratec (ETR:SBS) Aren't Appealing

Jul 12
Return Trends At Stratec (ETR:SBS) Aren't Appealing

Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate

Jun 27
Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate

Is Stratec (ETR:SBS) Using Too Much Debt?

May 25
Is Stratec (ETR:SBS) Using Too Much Debt?

Stratec's (ETR:SBS) Upcoming Dividend Will Be Larger Than Last Year's

Apr 02
Stratec's (ETR:SBS) Upcoming Dividend Will Be Larger Than Last Year's

The Returns At Stratec (ETR:SBS) Aren't Growing

Jan 28
The Returns At Stratec (ETR:SBS) Aren't Growing

Calculating The Fair Value Of Stratec SE (ETR:SBS)

Jan 12
Calculating The Fair Value Of Stratec SE (ETR:SBS)

Is Stratec (ETR:SBS) A Risky Investment?

Oct 26
Is Stratec (ETR:SBS) A Risky Investment?

Returns On Capital At Stratec (ETR:SBS) Have Stalled

Oct 11
Returns On Capital At Stratec (ETR:SBS) Have Stalled

Shareholder Returns

SBSDE Medical EquipmentDE Market
7D1.4%0.9%0.7%
1Y-24.5%-11.2%14.2%

Return vs Industry: SBS underperformed the German Medical Equipment industry which returned -11.1% over the past year.

Return vs Market: SBS underperformed the German Market which returned 14.6% over the past year.

Price Volatility

Is SBS's price volatile compared to industry and market?
SBS volatility
SBS Average Weekly Movement6.8%
Medical Equipment Industry Average Movement5.3%
Market Average Movement5.1%
10% most volatile stocks in DE Market12.5%
10% least volatile stocks in DE Market2.5%

Stable Share Price: SBS has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: SBS's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19791,420Marcus Wolfingerwww.stratec.com

Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and integrating instrumentation and software.

Stratec SE Fundamentals Summary

How do Stratec's earnings and revenue compare to its market cap?
SBS fundamental statistics
Market cap€272.90m
Earnings (TTM)€15.36m
Revenue (TTM)€260.25m
17.8x
P/E Ratio
1.0x
P/S Ratio

Is SBS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SBS income statement (TTM)
Revenue€260.25m
Cost of Revenue€185.90m
Gross Profit€74.36m
Other Expenses€59.00m
Earnings€15.36m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)1.26
Gross Margin28.57%
Net Profit Margin5.90%
Debt/Equity Ratio55.1%

How did SBS perform over the long term?

See historical performance and comparison

Dividends

2.7%
Current Dividend Yield
47%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/01 12:15
End of Day Share Price 2025/12/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Stratec SE is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Odysseas ManesiotisBerenberg
Michael HeiderBerenberg
Scott BardoBerenberg